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The efficacy of non-surgical treatment on pain and sensitization in patients with knee 1 
osteoarthritis: a pre-defined ancillary analysis from a randomized controlled trial 2 
INTRODUCTION 3 
Pain associated with knee osteoarthritis (OA) is recognized as a complex phenomenon 4 
encompassing several mechanisms1, indicating that its assessment2 and treatment3 should be 5 
multimodal to target all co-responsible mechanisms. Pain intensity, usage of pain medication, pain 6 
pattern and spreading of pain are important pain-related measures2, 4, 5. Another pain mechanism 7 
known to be important in patients with advanced knee OA is sensitization4, 6, 7, defined as increased 8 
responsiveness of nociceptive neurons to their normal input, and/or recruitment of a response to 9 
normally subthreshold inputs8.  10 
Quantitative sensory testing (QST) can be used to assess sensitization in patients with knee OA 11 
using a mechanism-based approach3. By assessing the somatosensory response evoked by applying 12 
controlled noxious or innocuous stimuli (e.g. using a pressure algometer) it is possible to quantify 13 
the sensitization of a patient9. Compared to healthy controls, pressure pain sensitivity found locally 14 
at the affected knee (and adjacent body parts) in patients with chronic pain can be associated with 15 
peripheral and/or central sensitization, while pressure pain sensitivity distantly from the knee may 16 
reflect generalized central sensitization (spreading sensitization) only4, 9. Both peripheral and 17 
spreading sensitization have previously been demonstrated in patients with knee OA compared to 18 
pain-free controls6, 10-14, although they have mostly been investigated in more advanced knee OA. 19 
Evidence regarding sensitization in patients with less advanced knee OA is scarce. 20 
While the evidence concerning the efficacy of non-surgical treatment on knee OA pain is strong15, 16, 21 
less attention has been paid to its efficacy on sensitization processes17, 18. Two previous studies have 22 
assessed the effects of exercise on sensitization in knee OA, but with conflicting results13, 19. 23 
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Henriksen et al.19 demonstrated that 12 weeks of supervised exercise reduced pressure pain 24 
sensitivity compared to a no-attention control group, while Kosek et al.13 found that exercise 25 
(average duration of 12 weeks) had no effect on pressure pain sensitivity. Furthermore, no studies 26 
have investigated the combined efficacy of the recommended treatments in reducing both pain and 27 
sensitization even though this could improve outcome18. 28 
A previously published20 randomized controlled trial (RCT) showed that a 3-month treatment 29 
program of neuromuscular exercise, education, diet, insoles and pain medication (the MEDIC-30 
treatment) resulted in greater long-term improvements in pain, function and quality of life outcomes 31 
compared to information and treatment advice (usual care) in patients with knee OA not eligible for 32 
total knee replacement (TKR). The aim of this pre-specified ancillary analysis was to investigate the 33 
efficacy of the MEDIC-treatment to improve different pain-related measures (pain intensity, pain 34 
location and pattern, spreading of pain and usage of pain medication) and sensitization after 3 35 
months compared to usual care. 36 
We hypothesized that the MEDIC-treatment would result in greater improvements in the pain-37 
related measures and sensitization than usual care at 3-month follow-up. 38 
METHOD 39 
Study design 40 
This was an ancillary analysis of the 3-month results from a two-arm parallel group assessor-41 
blinded RCT (1:1 treatment allocation) conforming to the CONSORT statement for reporting 42 
RCTs21. The current analyses were pre-defined in the statistical analysis plan (made available 43 
before unblinding the data)22. 44 
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All details of the recruitment process, full eligibility criteria, the process of randomization, 45 
allocation concealment and detailed description of the intervention have been published 46 
previously23.  47 
Patients 48 
One hundred patients with radiographic and symptomatic knee OA found not eligible for TKR by 49 
an orthopedic surgeon, but experiencing more than mild limitations, were enrolled. Patients were 50 
recruited from two specialized, public outpatient clinics at Aalborg University Hospital 51 
(Frederikshavn and Farsoe, 50 patients from each clinic) between 3 April 2012 and 12 July 2013. 52 
Major exclusion criteria were scores above 75 in the self-report questionnaire Knee Injury and 53 
Osteoarthritis Outcome Score (KOOS)4, defined as the average score for the subscale scores for 54 
pain, symptoms, activities of daily living (ADL) and quality of life (QOL), previous ipsilateral knee 55 
replacement and mean knee pain in the previous week greater than 60 mm on a 0–100 mm visual 56 
analogue scale (VAS). 57 
All patients gave informed consent before being enrolled, and the study was conducted in 58 
accordance with the Helsinki declaration and approved by the local Ethics Committee of The North 59 
Denmark Region (N-20110085). Furthermore, this ancillary study was registered at 60 
ClinicalTrial.gov (NCT02091830). 61 
Intervention 62 
The MEDIC-treatment 63 
The 3-month MEDIC-treatment consisted of prescribing education, exercise and insoles   to 64 
everyone in the MEDIC group, while weight loss and/or pain medication were prescribed if 65 
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indicated. The treatment was given at Aalborg University Hospital, Denmark, by physiotherapists 66 
and dieticians trained in providing the treatment to ensure standardization of the treatment program. 67 
Education 68 
Two 60-min sessions of education focusing on disease characteristics, OA pain and how to control 69 
and monitor it during exercise, treatment and help to self-help by actively engaging the patients.  70 
Exercise 71 
The MEDIC group participated in The NEuroMuscular EXercise training program (NEMEX), 72 
previously found feasible in patients with moderate to severe knee OA24, twice weekly with each 73 
session lasting 60 min. The program is based on neuromuscular and biomechanical principles with 74 
different levels of difficulty for each exercise24. To improve long-term adherence, the exercise 75 
program was followed by a transition period of 8 weeks to gradually accustom the patients to 76 
continue exercising at home.  77 
Dietary advice 78 
If patients had a body mass index (BMI) ≥25 at baseline, they underwent a dietary weight loss 79 
program based on principles from motivational interviewing, with instructions and advice related to 80 
the readiness of the individual patient to change dietary habits and take action25. It consisted of four 81 
60-min sessions, with the aim of reducing body weight by at least 5%26.  82 
Insoles 83 
A set of individually fitted full-length Formthotics System insoles with medial arch support (Foot 84 
Science International, Christchurch, New Zealand) was given to the patients. Patients with a knee 85 
knee-lateral-to-foot position (the knee moves over or lateral to the 5th toe in three or more of five 86 
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trials of the valid and reliable single limb mini squat test27) had a 4° lateral wedged added to their 87 
insole. 88 
Pain medication 89 
If found relevant, paracetamol 1 g four times daily, ibuprofen 400 mg three times daily, and 90 
pantoprazol 20 mg daily were prescribed. The prescription was reassessed every 3 weeks to 91 
supervise the use and indications of the medication. If the continuation of the pain medicine during 92 
the 3-week period was questioned by the patient (e.g. due to pain relief), the patients were 93 
instructed to contact the project physiotherapist. 94 
Usual care 95 
The usual care group was given two standardized information leaflets. These included information 96 
on knee OA with regard to etiology, symptoms, common functional limitations, recommended 97 
treatments and general advice on how to address the symptoms yourself and information on where 98 
in The North Denmark Region they could seek advice regarding treatment and general information 99 
on how to achieve a healthy lifestyle. The leaflets were designed to reflect current treatment of 100 
patients with knee OA in clinical practice, which has been demonstrated to be suboptimal compared 101 
to clinical guidelines28, 29 102 
Outcomes 103 
Both the baseline and 3-month follow-up were carried out at the Department of Occupational 104 
Therapy and Physiotherapy, Aalborg University Hospital, Denmark, by the same outcome assessor. 105 
The assessor was unaffiliated with the treatment sites, blinded to treatment allocation, and 106 
specifically trained in all aspects of the assessments. 107 
Assessment of pain 108 
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Peak pain intensity in the most affected knee during the previous 24 h was assessed on a 100 mm 109 
VAS with terminal descriptors of ‘no pain’ and ‘worst pain possible’. We chose peak pain intensity 110 
since it has been frequently applied in studies on sensitization in knee OA-related pain6, 7, 30. The 111 
VAS is a measure of pain widely used in patients with knee OA that is valid, reliable and 112 
responsive31.  113 
Pain intensity during function 114 
Knee pain intensity after 30 min of walking was assessed on a 100-mm VAS with terminal 115 
descriptors of ‘no pain’ and ‘worst pain possible’. Pain intensity after 30 min of walking was 116 
chosen, since it can serve as an indirect measure of how knee pain affects function.  117 
Knee pain location and pattern 118 
Knee pain location and pattern in the most affected knee were assessed using the reliable 119 
interviewer-administered questionnaire Knee Pain Map previously applied in patients with knee OA 120 
5. The Knee Pain Map identifies painful areas of the knee and characterizes the pain as localized, 121 
regional or diffuse5. Since diffuse pain is indicative of a more progressed sensitization4, the pain 122 
location and pattern were dichotomized (diffuse pain in the most affected knee yes/no).  123 
Spreading of pain 124 
The patients were asked to shade body sites with pain in the previous 24 hours on a region-divided 125 
body chart (26 sites in total). The number of pain sites was applied to classify the spreading of pain 126 
as previously suggested in a large-scale study on multisite pain32.  127 
Usage of pain medication 128 
7 
 
This was defined as any pain medication taken on a regular basis during the last week at baseline 129 
and at the 3-month follow-up. The results were dichotomized (pain medication yes/no) due to non-130 
uniformity of the distribution of pain medication intake.  131 
Assessment of sensitization 132 
Pressure pain thresholds (PPTs) were measured bilaterally using a handheld algometer with a 1 cm2 133 
probe (Algometer Type II, Somedic AB, Hoerby, Sweden). The pressure was applied perpendicular 134 
to the skin at a constant rate of 30 kPa/s until the patient felt the pressure change to pain and pressed 135 
a button defining the PPT. One or two test assessments were performed at the dorsal aspect of the 136 
hand to ensure that the patient understood the procedure. The test procedure has previously been 137 
assessed in a test-retest reliability and agreement study with 20 patients with knee OA that 138 
demonstrated intraclass correlation coefficients (2-way random-effects model, consistency-type) 139 
and 95 % limits of agreement (95% LOA; presented as the difference between the mean difference 140 
and the upper and lower LOA) ranging from 0.84 to 0.91 and 199.6 to 434.0 kPa33 for the different 141 
sites. The 95% LOA corresponds to the minimal detectable change (MDC) for the assessment 142 
method. 143 
Localized sensitization 144 
Localized sensitization (peripheral sensitization) was assessed using PPTs from four sites at the 145 
knee, all in proximity to the patella: (1) 3 cm medial to the midpoint of the medial edge, (2) 2 cm 146 
proximal to the midpoint of the superior edge, (3) 3 cm lateral to the midpoint of the lateral, and (4) 147 
at the centre6. PPTs were obtained twice at each site, and the mean of all four sites was used in the 148 
analyses. 149 
Spreading sensitization 150 
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Spreading sensitization (central sensitization) was assessed using PPTs from the tibialis anterior 151 
muscle (lower leg: 5 cm distal to the tibial tuberosity), and the extensor carpi radialis longus muscle 152 
(forearm: 5 cm distal to the lateral epicondyle of the humerus)6. PPTs were obtained twice at each 153 
site, and the means for the lower leg and for the forearm were used in the analyses. 154 
Statistical analysis 155 
Sample size 156 
The sample size was calculated based on the pre-defined primary hypothesis regarding peak pain 157 
intensity. The sample size needed to detect a 10-point difference (SD 14) between groups in peak 158 
pain intensity was 41 patients in each group (power of 90 % and a significance level at 0.05 (2-159 
sided)). To account for any TKRs performed during follow-up and for missing data, the dropout 160 
rate was set to 20%, and a total of 100 patients were randomized. Due to the ancillary nature of this 161 
pre-specified analysis, the sample size was deemed adequate for providing additional 162 
characterization of the effects of the MEDIC-treatment.  163 
Ancillary analyses 164 
Since this was an ancillary analysis, only patients (not undergoing a TKR) with available data from 165 
both the baseline and 3-month follow-up were included in the analyses. No adjustments for 166 
multiplicity were done as endorsed by The European Agency for the Evaluation of Medicinal 167 
Products when ancillary analyses are declared as supportive34.  168 
A Student’s t-test was used to evaluate change in pain intensity and number of pain sites between 169 
and within groups. A 3-way analysis of variance (ANOVA) was used to evaluate change in PPT 170 
from baseline to 3 months using the fixed factors group (MEDIC, usual care), site (knee, lower leg 171 
and forearm) and side (most affected, contralateral). The analysis was conducted both unadjusted 172 
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and adjusted (baseline PPT, gender and age). Within-group changes in PPTs due to  the treatment  173 
were further assessed using repeated measures ANOVA with time (baseline, 3 months) as the 174 
within-subject factor and site (knee, lower leg and forearm) and side (most affected, contralateral) 175 
as the between-subject factors for both the MEDIC group and the usual care group. The assumption 176 
of homogeneity of variance was tested using Levene’s test (P > 0.05), and the assumption of normal 177 
distribution was tested by visual inspection of Q-Q plots. If findings were non-significant, a 178 
sensitivity-analysis was performed that included only those participating in at least 75% of the 179 
exercise sessions. Tukey-Kramer was used as a post hoc test if ANOVA factors or interactions were 180 
significant.  181 
The relative risks for usage of pain medication and diffuse pain were estimated and compared 182 
between groups using a Poisson regression model with a robust error variance for the confidence 183 
intervals. 184 
The significance level was set at P < 0.05, and all analyses were performed in either IBM SPSS 185 
Statistics (Version 22, IBM Corporation, Armonk, NY, USA) or Stata 13 (StataCorp, College 186 
Station, TX, USA). 187 
RESULTS 188 
In all, 654 patients seen in secondary care by an orthopedic surgeon were assessed for eligibility, 189 
553 were excluded, and one was not willing to undergo randomization. The primary reasons for 190 
exclusion were being eligible for a TKR (n = 192), no radiographic OA (Kellgren-Lawrence score < 191 
1; n = 87), and inability to comply with the study protocol (n = 159). One hundred patients were 192 
randomized, with 43/50 (86%; one patient underwent TKR during the 3 months) in the MEDIC 193 
group and 46/50 (92%) in the usual care group completing both baseline and 3-month follow-up. 194 
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For further information on the study flow, please refer to20. Patient characteristics of the groups at 195 
baseline are presented in Table 1 and pain location and pattern at baseline are presented in Table 2. 196 
Between-group analyses 197 
Peak pain intensity 198 
There was a statistically significant difference in change (95 % CI) from baseline to 3 months of 199 
15.4 (2.6 to 28.2) in peak pain intensity (P = 0.019), favoring the MEDIC group. 200 
Pain intensity during function 201 
There was a statistically significant difference in change (95% CI) from baseline to 3 months of 202 
32.6 (18.1 to 45.0) in pain intensity after 30 min of walking (P < 0.001) favoring the MEDIC group. 203 
Knee pain location and pattern 204 
There was no significant difference between groups in the number of patients with diffuse pain at 3 205 
months compared to baseline.  206 
Spreading of pain 207 
There was a statistically significant difference in change (95% CI) from baseline to 3 months of 208 
0.86 (0.03 to 1.70) in number of sites with pain (P = 0.042), favoring the MEDIC group.  209 
Figure 1 illustrates the difference in body sites with pain at baseline and after 3 months in the 210 
MEDIC group and the usual care group.  211 
Usage of pain medication 212 
There was no significant difference between groups in the usage of pain medication at 3 months 213 
compared to baseline.  214 
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Localized and spreading sensitization 215 
No statistical difference in change in PPTs from baseline to 3 months was found between groups in 216 
the crude analysis (F(1,468) = 0.028, P = 0.868) or when adjusting for baseline PPT, age and gender 217 
(F(1,465) = 0.015, P = 0.902; Fig. 2). Including only those participating in at least 75% of the 218 
exercise sessions in the MEDIC group still demonstrated no statistical difference in change in PPTs 219 
from baseline to 3 months between groups (F(1,366) = 0.585, P = 0.445). 220 
Within-group analyses 221 
Within-group results are presented in Tables 3–5. 222 
DISCUSSION 223 
This study showed that a 3-month non-surgical treatment program was associated with greater 224 
improvements in outcome with regard to pain intensity and spreading of bodily pain, but not 225 
sensitization, knee pain pattern and usage of pain medication after 3 months compared to 226 
information and treatment advice in patients with knee OA not eligible for TKR. These findings 227 
confirm that pain has a multitude of facets, and that treatment results may differ depending on what 228 
pain-related measures are evaluated. This is the first study evaluating multiple pain-related 229 
measures, including sensitization, in a randomized setting in patients with knee OA. 230 
Comparison to previous studies on pain 231 
We demonstrated large between-group differences with regard to change in pain intensity from 232 
baseline to 3 months, confirming previous RCTs on the efficacy of a non-surgical treatment 233 
program in reducing pain in patients with knee OA35, 36. Furthermore, our study extends these 234 
findings by adhering to the recommendation that other aspects of the complexity of pain than pain 235 
intensity alone should be addressed2, thus giving a broad perspective on the effects of a non-surgical 236 
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treatment program in patients with knee OA. In addition to improvements in pain intensity, we 237 
demonstrated that the MEDIC group had a larger reduction in the number of body sites with pain 238 
following the treatment as compared with the usual care group and a within-group reduction in the 239 
proportion using pain medication. This could be related to systemic anti-inflammatory effects from 240 
exercise that have previously been suggested to be the reason for the protective effects of exercise 241 
on cardiovascular disease and type 2 diabetes37 and improvements in well-being and other 242 
psychosocial components that have been demonstrated to result from exercise38. Furthermore, 243 
education, i.e. teaching the patient about the etiology of the pain and how to deal with it, is known 244 
to be effective in the treatment of chronic musculoskeletal pain39, thereby offering an additional 245 
explanation for the findings. Either way, the reduction of total body sites with pain as a result of 246 
non-surgical treatment of the knee is promising because musculoskeletal pain has been suggested to 247 
spread over time4, and because having pain elsewhere is significantly associated with persistent pain 248 
after joint replacement 40-42. A recent study applying the same region-divided body chart that we 249 
used demonstrated that patients with chronic knee pain after revision TKR (all undergoing their 250 
primary TKR due to knee OA) had a mean of six body sites with pain and a mean pain duration of 251 
approx. 14 years43, while the patients in our study had a mean of three body sites with pain and only 252 
28% of the patients had had knee pain for more than 10 years. Even though a direct linkage between 253 
the spreading of pain and the duration cannot be established based on cross-sectional data, these 254 
results offers some support to the proposition that pain will become widespread over time if not 255 
treated properly4 This notion is further supported by a prospective study by Andersen et al.44 256 
showing that chronic pain in the knees increase the risk of developing chronic pain elsewhere over 257 
time. This highlights the potential of multimodal treatment for pain relief in patients with knee OA. 258 
Comparison to previous studies on sensitization 259 
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While the previous studies investigating the efficacy of exercise on sensitization in knee OA, a 260 
RCT19 and a controlled before-and-after study13, both included a passive control group, we advised 261 
our control group to initiate non-surgical treatment on their own, thereby resembling contemporary 262 
treatment in patients with knee OA found not eligible for TKR. In the MEDIC group of our study, 263 
the proportion with diffuse knee pain was reduced following treatment indicating an improvement 264 
in sensitization. In both groups, improvements were seen in measures reflecting localized 265 
sensitization (peripheral sensitization: PPTs from the knee) and spreading sensitization (central 266 
sensitization: PPTs from the lower leg and forearm), but we found no significant difference in 267 
sensitization between groups. Furthermore, the improvements within groups were smaller than the 268 
MDC for handheld algometry33, which is why it cannot be ruled out that the lack of difference 269 
between groups was actually caused by measurement uncertainty. Differences in measurement 270 
uncertainty could also help explain the conflicting results in the two previous studies, since the 271 
study by Kosek et al.13 also applied a handheld algometer in the assessment of sensitization, while 272 
Henriksen et al.19 applied a computer-controlled cuff algometer that is less affected by measurement 273 
variability45. However, it is important to recognize that the differences in PPT found by Henriksen 274 
et al.19 were small and of questionable clinical relevance. All together, this indicates that 275 
sensitization may not be an ideal outcome measures in trials in the general population of patients 276 
with knee OA.  277 
Sensitization in knee osteoarthritis – only relevant for a subgroup of patients?  278 
The so far conflicting results on the effects of non-surgical treatment on sensitization compared to 279 
the vast body of evidence supporting the effects of the same treatments on pain16 could potentially 280 
be explained by the presence of subgroups of OA patients with more sensitization and OA patients 281 
with less or no sensitization46, 47. Despite similar clinical pain intensities, a subgroup of patients 282 
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with knee OA who had high local knee pain sensitivity to pressure had higher pain sensitivity to 283 
pressure at the lower leg and the forearm than those with low local knee pain sensitivity7. This 284 
highlights that subgroups with more pronounced sensitization exist within a group of patients with 285 
knee OA with similar severities of symptomatic knee OA. Subgroups may however exist even 286 
among those considered being healthy, since the variability in PPTs is large in a healthy 287 
population48. PPTs from the knee (approx. 600 kPa), lower leg (approx. 500 kPa) and forearm 288 
(approx. 350 kPa) in pain-free subjects of comparable age and gender distribution6 are similar to 289 
those demonstrated at baseline in our study. In the same study, those severely affected by 290 
sensitization had a mean knee pain intensity of 80 out of 1006, indicating a more progressed knee 291 
OA than the study population in our study (mean pain of 58 out of 100). Since knee OA pain 292 
intensity is related to the severity of the sensitization6, 7, 12, 30, 49, this suggests that the pain 293 
sensitization may not yet have developed into a clinical relevant parameter in our study population, 294 
potentially explaining the non-significant differences between groups. Targeting non-surgical 295 
treatment of sensitization towards those actually affected by the problem has the potential to 296 
desensitize the central nervous system by affecting mechanisms involved in the sensitization18. 297 
Limitations 298 
The nociceptive input in knee OA could originate from several sources, including periarticular 299 
tissues, inflammation, elevated intraosseous pressure in the subchondral bone, and elevation of 300 
periosteum by osteophyte growth50. Since the PPTs of our study were not specific to all these 301 
structures, it is unclear whether PPTs actually reflect the true pain and sensitization of the knee OA 302 
joint. However, the PPT measurement sites have been applied in several previous studies 303 
successfully differentiating between different levels of sensitization in patients with knee pain6, 7, 12, 304 
43. Due to the multimodal setup of the treatment program, it is unknown whether all components of 305 
the MEDIC-treatment are required for the improvements in pain outcomes, and at the same time, 306 
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the multimodal setup makes it impossible to identify the efficacy of an individual treatment 307 
modality alone. However, since the treatment program adheres to current guidelines on the 308 
treatment of knee OA15, 16 and is embedded in secondary health care, the strengths of the design are 309 
considered to outweigh the limitations.  310 
Conclusions 311 
A combined treatment with neuromuscular exercise, patient education, diet, insoles and pain 312 
medication resulted in greater improvements in pain intensity and spreading of pain outcomes than 313 
usual care (information and advice) in patients with knee OA not eligible for TKR. For this patient 314 
population no differences in effect were seen on sensitization parameters, knee pain pattern and 315 
usage of pain medication after 3 months of the combined treatment compared to usual care. This 316 
suggests that sensitization, as measured in our study, is less useful as an outcome measure in trials 317 
of the general knee OA population.  318 
 319 
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FIGURE LEGENDS 533 
Figure 1. Pressure pain thresholds on the most affected side. Mean pressure pain thresholds 534 
(PPT) measured in kPa using a handheld algometer on the knee, lower leg and forearm. No 535 
between-group differences were found, while significantly higher PPTs (*; P < 0.05) were found for 536 
all sites on both the most affected and contralateral side after 3 months in both the MEDIC group 537 
and the usual care group. Error bars indicate 95% confidence intervals. 538 
 539 
Figure 2. Pain sites. Sites of the body where at least 10% of the patients in the MEDIC group (A) 540 
and in the usual care group (B) reported pain during the previous 24 hours. A black shade indicates 541 
that at least 10% reported pain at both baseline and at the 3-month follow-up, while a grey shade 542 
indicates that at least 10% reported pain at baseline, but not at the 3-month follow-up. The right side 543 
of the body in the figures has been set as the side mostly affected by knee osteoarthritis. 544 
 545 
 546 
 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
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TABLES 558 
Table 1. Patient characteristics 559 
Patient characteristics  MEDIC Usual Care 
Women, n (%) 26 (52) 25 (50) 
Age (years), mean (SD) 64.8 (8.7) 67.1 (9.1) 
Body mass index, mean (SD) 30.6 (5.6) 29.4 (5.2) 
Study knee, n right (%) 18 (36) 27 (54) 
Bilateral knee pain, n (%) 18 (36) 21 (42) 
Duration of knee symptoms, n (%)   
     0–6 months 4 (8) 2 (4) 
     6–12 months 9 (18) 6 (12) 
     1–2 years 10 (20) 5 (10) 
     2–5 years 11 (22) 13 (26) 
     5–10 years 4 (8) 8 (16) 
    More than 10 years 12 (24) 16 (32) 
Radiographic knee OA severity (Kellgren-Lawrence), n (%)   
    Grade 1 7 (14) 11 (22) 
    Grade 2 13 (26) 15 (30) 
    Grade 3 13 (26) 10 (20) 
    Grade 4 17 (34) 14 (28) 
Peak pain intensity in the previous 24h (0–100), mean (SD) 60 (23) 56 (25) 
Pain intensity after 30 min walking (0–100), mean (SD) 62 (26) 47 (24) 
Have used pain medication in the last week, n (%) 32 (64) 30 (60) 
Body sites with pain, mean (SD) 3.2 (2.9) 2.8 (2.1) 
 560 
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Table 2. Pain location and pattern at baseline in the most affected knee 561 
Pain location and pattern, n (%) MEDIC (n=49) Usual Care (=47) 
Diffuse1 34 (69) 26 (55) 
Regional 13 (27) 21 (45) 
    Medial region 9 (18) 12 (26) 
    Patella region 2 (4) 2 (4) 
    Lateral region 1 (2) 3 (6) 
    Back of knee, regional 0 (0) 0 (0) 
Localized 13 (27) 21 (45) 
    Superior medial 1 (2) 0 (0) 
    Medial joint line 10 (20) 13 (28) 
    Inferior medial 4 (8) 6 (13) 
    Patella, local 2 (4) 2 (4) 
    Superior lateral 0 (0) 1 (2) 
    Lateral joint line 1 (2) 3 (6) 
    Inferior lateral 1 (2) 3 (6) 
    Back of knee, local 0 (0) 0 (0) 
1Of these 20 in the MEDIC group and 13 in the usual care group were classified as diffuse pain due to either 562 
>3 areas of localized pain, >2 regions of pain, and/or >1 location and 1 non-overlapping region32, 33. 563 
 564 
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Table 3. Within-group analyses 569 
Outcome MEDIC group   Usual Care group  
 F statistics (df) or 
Mean improvements 
(95% CI) 
P value F statistics (df) or 
Mean improvements 
(95% CI) 
P value 
Peak pain intensity 27.9 (18.4 to 37.5) <0.001 13.4 (4.3 to 22.5) 0.005 
Pain intensity after walking 34.8 (25.0 to 44.6) <0.001 2.7 (-6.9 to 12.3) 0.574 
Body sites with pain 1.19 (0.49 to 1.89) 0.001 0.33 (-0.16 to 0.81) 0.179 
Pressure pain thresholds1 48.293 (1, 240) <0.001 31.661 (1, 228) <0.001 
1 There was a significant interaction between time and site (F(2,240) = 3.242, P = 0.041; Fig. 1A) in 570 
the MEDIC group demonstrating that within-group changes from baseline to 3 months were larger 571 
for PPTs from the lower leg than for the knee and the forearm. No other interactions were found. 572 
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Table 4. Diffuse knee pain in the most affected knee 584 
Outcome MEDIC group  
(95% CI)  
Usual Care 
group 
 (95% CI)   
Proportion with diffuse knee pain1 (nMEDIC, nusual care)   
Baseline (41, 40) 0.78 (0.63 to 
0.88) 
0.53 (0.37 to 
0.68) 
3 months (41, 40) 0.45 (0.31 to 
0.61) 
0.40 (0.26 to 
0.56) 
Risk ratio for having diffuse pain at 3 months vs. baseline   
Crude estimate 0.47 (0.32 to 
0.69) 
0.76 (0.52 to 
1.12) 
Risk ratio for having diffuse pain at 3 months in the usual care group 
vs. MEDIC group 
  
Crude estimate 0.91 (0.52 to 
1.60) 
--------------- 
1 The definition of diffuse knee pain is from the Knee Pain Map32, 33. 585 
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Table 5. Usage of pain medication 590 
Outcome MEDIC group 
 (95% CI)  
Usual Care 
group  
(95% CI)   
Proportion of users of pain medication1 (nMEDIC, nusual care)   
Baseline (42, 44) 0.69 (0.53 to 
0.81) 
0.55 (0.40 to 
0.69) 
3 months (42, 44) 0.45 (0.31 to 
0.61) 
0.66 (0.51 to 
0.78) 
Risk ratio for taking pain medication at 3 months vs. baseline   
Crude estimate 0.66 (0.47 to 
0.92) 
1.21 (0.92 to 
1.58) 
Risk ratio for taking pain medication at 3 months in the usual care 
group vs. MEDIC group 
  
Crude estimate 1.46 (0.98 to 
2.17) 
--------------- 
1 User of pain medication was defined as patients taking pain medication of any kind on a regular basis 591 
during the last week. 592 
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